Works by Gauvin, Jennifer

Results: 3
    1

    Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors.

    Published in:
    2020
    By:
    • Tolcher, Anthony W.;
    • Kurzrock, Razelle;
    • Valero, Vincente;
    • Gonzalez, Rene;
    • Heist, Rebecca S.;
    • Tan, Antoinette R.;
    • Means-Powell, Julie;
    • Werner, Theresa L.;
    • Becerra, Carlos;
    • Wang, Chenxi;
    • Leonowens, Cathrine;
    • Kalyana-Sundaram, Shanker;
    • Kleha, Joseph F.;
    • Gauvin, Jennifer;
    • D'Amelio, Anthony M.;
    • Ellis, Catherine;
    • Ibrahim, Nageatte;
    • Yan, Li;
    • D'Amelio, Anthony M Jr
    Publication type:
    journal article
    2
    3

    A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.

    Published in:
    Investigational New Drugs, 2018, v. 36, n. 6, p. 1016, doi. 10.1007/s10637-018-0591-z
    By:
    • Aghajanian, Carol;
    • Bell-McGuinn, Katherine M.;
    • Burris, Howard A.;
    • Siu, Lillian L.;
    • Stayner, Lee-Ann;
    • Wheler, Jennifer J.;
    • Hong, David S.;
    • Kurkjian, Carla;
    • Pant, Shubham;
    • Santiago-Walker, Ademi;
    • Gauvin, Jennifer L.;
    • Antal, Joyce M.;
    • Opalinska, Joanna B.;
    • Morris, Shannon R.;
    • Infante, Jeffrey R.
    Publication type:
    Article